(Adnkronos) - Al fine di garantire una risposta sempre migliore ai bisogni di salute delle persone con diabete, Regione Lombardia ha deciso di estendere a tutti i pazienti diabetici l’accesso gratuito ai sistemi di monitoraggio glicemico più innovativi. Con la delibera n°XII / 1827, Regione Lombardia estende infatti la prescrivibilità a carico del Ssr dei sistemi di monitoraggio Flash del glucosio, con sensori come il FreeStyle Libre di Abbott, oltre che ai pazienti con diabete tipo 1, anche a tutti i pazienti diabetici di tipo 2 in terapia insulinica basale e, per la prima volta in Europa, ai pazienti diabetici di tipo 2 in terapia ipoglicemizzante orale per un periodo di tre mesi.
Category
🗞
NewsTranscript
00:00 In Lombardy, all people with diabetes can access free glucose monitoring devices with sensors.
00:11 To establish this, the new criteria for regional eligibility, just issued by the Lombardy Region,
00:16 with which the prescribability is extended in charge of the regional health system,
00:20 of the glucose flash monitoring systems with sensors such as Abbott's Freestyle Libre,
00:25 as well as patients with type 1 diabetes, all type 2 diabetic patients in basal insulin therapy
00:31 and, for the first time in Europe, type 2 diabetic patients in oral hypoglycemic therapy for a period of three months.
00:38 We are starting to experiment the future here in the Lombardy Region, a region with 587,000 type 2 diabetics,
00:45 a great attention to all diabetic patients, one of the first chronic diseases of our country.
00:52 Technology also allows us to reduce health spending because this attention,
00:58 which not only improves the patient's life, but also improves regional health spending.
01:04 So, in this direction, we are innovating towards the future with targeted investments.
01:09 The use of glucose levels monitoring systems in the blood has a positive impact on clinical outcomes
01:15 and promotes a more active involvement of the patient in the effective management of the pathology.
01:19 As a testimony to the results of the recent study conducted by the Iniguarde Hospital and the Brescia Hospital
01:25 on people with type 2 diabetes in basal insulin therapy or oral therapy using Abbott's Freestyle Libre 2.
01:32 We have shown that in a population of patients affected by type 2 diabetes or type 2 diabetes in basal insulin therapy,
01:39 the system has been able to reduce, to obtain a reduction of 0.4% of the glycated hemoglobin
01:47 and in 6-3 months also a reduction of the hypoglycemia rate.
01:51 So, a significant improvement in the glycemic balance in a population of patients affected by type 2 diabetes
01:58 quite frequent, about 1 in 5 diabetic patients have this type of therapy, so a significant result.
02:05 Thanks to the most innovative self-monitoring systems, equipped with sensors capable of transmitting minute by minute
02:11 the data directly to the patient's smartphone without even the need for scanning,
02:15 people with diabetes not only no longer have to point their fingers every day,
02:19 but also have the possibility of easily accessing the data they need to live a healthier life.
02:25 The advantages of the flash or the intermittent sensor, in my opinion, as a patient and as a patient representative,
02:35 I say that it will be huge, and it will be huge mainly for two factors.
02:41 First, because it makes the person who carries it aware and aware.
02:46 Second, because it optimizes metabolic control.
02:50 I'm out.